Try FOLFOX-HAIC combining bevacizumab or cetuximab for initially unresectable colorectal liver metastasis patients to increase the conversion to resection rate to improve long-term survival outcomes
age 18-75 years
no history of other malignant diseases
refuse or progress in prior systemic treatment
diagnosed as CRLM confirmed by pathology, in spite of whether the primary tumor had been resected
extra-hepatic metastasis verified by medical imaging
unable to tolerate chemotherapy, anesthesia or surgery
allergy or previous intolerable to any agent of oxaliplatin, leucovorin, 5-Fu, bevacizumab or cetuximab
tumor spread in abdomen